Form4insider filings, from the source

SEC Form 4 · accession 0001652917-15-000006

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
George Yancopoulos
Officer — President Regeneron Laboratori · Director
Period of report
Oct 30, 2015
Accepted (ET)
Nov 3, 2015 · 4:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockOct 30, 2015M182,818$11.64A682,818D
Common StockOct 30, 2015F3,806$559.08D679,012D
Common StockOct 30, 2015F92,316$559.08D586,696D
Common StockF2Nov 2, 2015S1,200$561.75D585,496D
Common StockNov 2, 2015S100$562.36D585,396D
Common StockF3Nov 2, 2015S530$563.76D584,866D
Common StockF4Nov 2, 2015S1,000$564.57D583,866D
Common StockF5Nov 2, 2015S1,000$565.89D582,866D
Common StockF6Nov 2, 2015S1,700$566.66D581,166D
Common StockF7Nov 2, 2015S1,350$567.61D579,816D
Common StockF8Nov 2, 2015S1,600$568.49D578,216D
Common StockF9Nov 2, 2015S2,223$569.47D575,993D
Common StockF10Nov 2, 2015S6,330$570.67D569,663D
Common StockF11Nov 2, 2015S7,800$571.41D561,863D
Common StockF12Nov 2, 2015S5,723$572.43D556,140D
Common StockF13Nov 2, 2015S2,629$573.47D553,511D
Common StockF14Nov 2, 2015S2,693$574.55D550,818D
Common StockF15Nov 2, 2015S2,441$575.64D548,377D
Common StockF16Nov 2, 2015S865$576.48D547,512D
Common StockF17Nov 2, 2015S1,996$577.58D545,516D
Common StockF18Nov 2, 2015S268$578.73D545,248D
Common StockF19Nov 2, 2015S1,500$579.53D543,748D
Common StockF20Nov 2, 2015S400$580.29D543,348D
Common Stockholding———5,654IBy 401(k) Plan
Common Stockholding———569,588Iby Trust

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Non-Qualified Stock Option (right to buy)F21$11.64Oct 30, 2015M182,818D—Dec 19, 2015Common Stock182,8180D

Explanation of responses